The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...